Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Alemtuzumab 12 mg
BIOLOGICAL
2 trials
Sponsors
Genzyme, a Sanofi Company
Conditions
Multiple Sclerosis, Relapsing-Remitting
Phase 2
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
Completed
NCT00050778
Genzyme, a Sanofi Company
Multiple Sclerosis, Relapsing-Remitting
Start: 2002-12-31
End: 2010-01-31
Updated: 2015-01-08
Phase 3
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
Completed
NCT00548405
Genzyme, a Sanofi Company
Multiple Sclerosis, Relapsing-Remitting
Start: 2007-10-31
End: 2011-09-30
Updated: 2017-04-17
Related Papers
Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study
Therapeutic Advances in Neurological Disorders
2025-01-01
2 citations
SCALA: a randomized phase I trial comparing subcutaneous and intravenous alemtuzumab in patients with progressive multiple sclerosis.
2024-11-06
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
Therapeutic Advances in Neurological Disorders
2023-01-01
18 citations
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
Multiple Sclerosis Journal - Experimental Translational and Clinical
2023-01-01
7 citations
CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis.
2021-12-04
24 citations
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.
2021-06-24
3 citations
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
Therapeutic Advances in Neurological Disorders
2021-01-01
44 citations
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years.
2020-12-24
14 citations
Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years
Multiple Sclerosis Journal - Experimental Translational and Clinical
2020-10-01
15 citations
What's happening in <i>Neurology® Neuroimmunology & Neuroinflammation</i>
Neurology
2020-07-28
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study
CNS Drugs
2020-07-24
55 citations
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.
2020-06-24
38 citations
Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
2020-06-15
44 citations
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies.
2020-05-14
6 citations
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
2020-05-06
23 citations
Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
Multiple Sclerosis Journal
2019-11-01
19 citations
Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.
2019-10-29
31 citations
Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study).
2019-10-25
8 citations
ECTRIMS 2019 - Poster Session 1
Multiple Sclerosis Journal
2019-09-01
13 citations
Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis
Multiple Sclerosis Journal
2019-05-30
17 citations
61 more papers not shown